Myriad Genetics | MYGN - Gross Profit On Sales


Myriad Genetics reported $146.8M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Agilent USD 990M 44M Mar/2026
Becton, Dickinson and Co. USD 2.15B 257M Mar/2026
Bio-Rad Laboratories USD 345.2M 1.8M Dec/2025
Bruker USD 379.8M 69.4M Mar/2026
Danaher USD 3.59B 375M Mar/2026
Illumina USD 721M 38M Mar/2026
J&J USD 17.24B 642M Mar/2026
Mettler Toledo International USD 675.44M 65.98M Dec/2025
Myriad Genetics USD 146.8M 3M Dec/2025
OraSure Technologies USD 11.34M 435K Dec/2025
Pacific Biosciences Of California USD 15.74M 601K Dec/2025
Quest Diagnostics USD 906M 33M Mar/2026
Quidel USD -91.8M 366.6M Mar/2026
Repligen USD 108.28M 4.45M Mar/2026
Revvity USD 387.66M 34M Mar/2026
Standard Biotools USD 11.38M 1.9M Dec/2025
Thermo Fisher Scientific USD 4.49B 146M Mar/2026
Veracyte USD 101.16M 814K Mar/2026
Waters USD 542M 15.42M Mar/2026